Skip to main content

Table 2 Distribution and characteristics of FDG-avid supradiaphragmatic lymph nodes (sdLNs) in PET/CT

From: Behavior of FDG-avid supradiaphragmatic lymph nodes in PET/CT throughout primary therapy in advanced serous epithelial ovarian cancer: a prospective study

 

Pre-operative PET/CT

Treatment response evaluation PET/CT

The 1st relapse PET/CT

The anatomical site of FDG-avid sdLNs

Patients with FDG-avid sdLNs N (%)

Mean short axis mm(±sd)

Mean SUVmax (±sd)

Patients with FDG-avid sdLNs N (%)

Mean short axis mm(±sd)

Mean SUVmax (±sd)

Patients with FDG-avid sdLNs N (%)

Mean short axis mm(±sd)

Mean SUVmax (±sd)

Responders group (N = 29)

 Parasternal

17 (59)

5.6(±2.3)

2.7(±0.8)

2 (7)

2.2(±1.9)

1.7(±0.5)

7 (32)

5.7(±2.5)

4.0(±2.3)

 Subclavian

4 (14)

8.0(±2.3)

4.8(±1.9)

1 (3)

8.0(±3.2)

4.8

2 (9)

8.0(±3.6)

6.4(±4.3)

 Axillary

12 (41)

9.1(±4.4)

4.4(±3.9)

5 (17)

6.3(±3.2)

2.0(±0.8)

4 (18)

14.9(±7.0)

11.1(±9.4)

 Mediastinal

8 (28)

8.5(±2.5)

4.3(±1.8)

3 (10)

5.5(±2.9)

2.9(±0.3)

9 (41)

7.3(±1.4)

5.6(±3.5)

 Cardiophrenic

23 (79)

7.7(±4.4)

3.4(±2.1)

3 (10)

4.8(±1.6)

1.9(±0.05)

7 (32)

7.8(±6.2)

3.8(±3.4)

Total

29 (100)

7.6(±3.8)

3.6(±2.4)

10 (34)

5.5(±2.9)

2.3(±0.9)

13 (59) of 22

8.6(±5.5)

6.0(±5.6)

  Multiple sites

20 (69)

  

4 (14)

  

8 (36)

  

  Single site

9 (31)

  

6 (20)

  

5 (23)

  

Non-responders group (N = 12)

 Parasternal

11 (92)

4.9(±1.4)

2.9(±0.5)

5 (42)

8.5(±8.7)

1.8(±0.8)

   

 Subclavian

2 (17)

14.3(±5.3)

6.2(±0.9)

1 (8)

5.0

3.8(±0.7)

   

 Axillary

2 (17)

13.0(±5.1)

5.7(±3.1)

0

   

 Mediastinal

6 (50)

12.4(±6.7)

5.2(±2.4)

3 (25)

8.2(±2.2)

3.3(±1.6)

   

 Cardiophrenic

8 (67)

6.8(±1.6)

3.2(±1.2)

6 (50)

5.1(±1.4)

2.8(±1.2)

   

Total

12 (100)

8.1(±5.1)

3.8(±2.0)

7 (58)

6.8(±4.9)

2.9(±1.4)

   

  Multiple sites

11 (92)

  

3 (25)

     

  Single site

1 (8)

  

4 (33)

     
  1. Distribution and characteristics of FDG-avid supradiaphragmatic lymph nodes (sdLNs) in PET/CT in patients with advanced stage epithelial ovarian cancer at different time points of the disease